Emend Risk Program To Ensure Prescribers Understand Approved Indication

Merck's risk management program for Emend will emphasize the anti-emetic's approved indication to deter prescribing for non-approved indications

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet